We are delighted to welcome Afortiori Bio to Stevenage Bioscience Catalyst, strengthening our growing community of innovative therapeutics companies.

Afortiori Bio is a preclinical stage RNA therapeutics company developing targeted RNA medicines for chronic liver disease. Their science focuses on tackling liver fibrosis, a major area of unmet need, with the ambition to halt and reverse disease progression and improve outcomes for patients.

As Nicola Wall, CEO and Founder of Afortiori Bio, commented:

“Joining Stevenage Bioscience Catalyst places us within a highly collaborative scientific environment at a pivotal stage for the company. Being part of a campus that understands both science and translation will help us accelerate the development of our RNA therapeutics for patients.” 

Team Afortiori Bio join SBC’s Seed Works

We are proud to continue building a campus that supports and attracts women led therapeutics companies.

Find out more about Afortiori Bio at afortioribio.com.